We’re excited to share that Robert Aleksandrowicz, CEO of Cellis, was featured in the latest Innovator Spotlight interview by Dealflow.eu! This marks another milestone for our company following our victory at the Innovation Radar Prize 2024.
In the interview, Robert highlights the breakthrough potential of our Macrophage Drug Conjugate (MDC) technology, an innovative cell-based immunotherapy designed to reprogram the tumor microenvironment and overcome drug resistance in aggressive cancers. This approach opens new possibilities in oncology, offering hope to patients who have exhausted conventional treatment options.
As Robert puts it:
🗨️ “Our vision is clear: we see MDC technology as a game-changer in oncology and immunotherapy. The success of our clinical trials has the potential to bring hope to millions of patients worldwide.”
At Cellis, we are committed to pushing the boundaries of cancer treatment, and we’re grateful for the recognition from Dealflow.eu.
📖 Read the full interview here: https://dealflow.eu/innovator-spotlight-with-robert-aleksandrowicz-from-cellis/
